Androgenetic Alopecia Epidemiology Forecast 2025-2034

It is estimated that 50 million men and 30 million women are affected by androgenetic alopecia in the United States. This form of hair loss can start as early as an individual’s teens, with the risk increasing with age.

Androgenetic Alopecia Epidemiology Forecast Report Coverage

The “Androgenetic Alopecia Epidemiology Forecast Report 2025-2034” offers comprehensive information on the prevalence and demographics of androgenetic alopecia. It projects the future incidence and prevalence rates of androgenetic alopecia across various populations. The study covers age, gender, and type as major determinants of the androgenetic alopecia-affected population. The report highlights patterns in the prevalence of androgenetic alopecia over time and projects future trends based on multiple variables.

The report provides a comprehensive overview of the disease, as well as historical and projected data on the epidemiology of androgenetic alopecia in the 8 major markets.

Regions Covered

• The United States
• EU-4 (Germany, France, Italy, Spain) and the United Kingdom
• Japan
• India

Androgenetic Alopecia Disease Overview

Androgenetic alopecia refers to a common form of hair loss observed both in men (male pattern baldness) and women (female pattern hair loss). In men, the hair thins at the top of the head and the hairline recedes, usually progressing to a state of partial or complete baldness. In women, although the hair turns thinner at the crown, the hairline typically doesn’t recede and total baldness is rare. Several factors including genetic and environmental conditions contribute to this condition.

Androgenetic Alopecia: Treatment Overview

Over-the-counter (OTC) medications such as minoxidil (Rogaine®) are generally used as the first course of treatment for androgenetic alopecia. Prescription oral medications like finasteride (Propecia) also help in treating male pattern baldness. However, certain side effects such as testicular pain, allergic reactions, and erectile dysfunction might be observed. Other hair loss treatment options include hair transplants and platelet-rich plasma injections.

Epidemiology

The androgenetic alopecia epidemiology section offers information on the patient pool from history to the present as well as the projected trend for each of the 8 major markets. The publisher provides both current and predicted trends for androgenetic alopecia by examining a wide range of studies. Additionally, the report covers the diagnosed patient pool for androgenetic alopecia and their trends. The data is broken down into specific categories, such as total prevalent cases in males and females, and total diagnosed cases across different age groups and patient pools.

• Androgenetic alopecia is estimated to affect around 50% of men who are over 50 years old and 50% of women who are over 65 years of age. It can also affect younger women and men.
• The risk of developing androgenetic alopecia increases with age, with around 25% of males observing the first signs of hair loss before reaching the age of 21 years. By age 50, roughly half experience the loss of hair, and nearly 70% will lose hair as their age increases further. In women, the incidence of androgenetic alopecia shows a significant rise after menopause.
• Androgenetic alopecia shows a strong familial predisposition, with sons showing a 5 to 6 higher relative risk of the condition if their fathers have balding.
• Caucasian individuals show the highest prevalence of androgenetic alopecia, followed by Asians, African Americans, Native Americans, and Inuit populations. In Caucasian males, the incidence is closely aligned with age as around 50% are affected by age 50, and 80% experience androgenetic alopecia by age 70.

Country-wise Androgenetic Alopecia Epidemiology

The androgenetic alopecia epidemiology data and findings for the United States, EU-4 (Germany, Spain, Italy, France), the United Kingdom, Japan, and India are also provided in the epidemiology section.

The epidemiology of androgenetic alopecia differs between countries due to factors such as genetics, lifestyle patterns, dietary habits, environmental influences, and healthcare access. In the United States, approximately 50 million men and 30 million women have androgenetic alopecia.

Scope of the Report

• The report covers a detailed analysis of signs and symptoms, causes, risk factors, pathophysiology, diagnosis, treatment options, and classification/types of androgenetic alopecia based on several factors.
• Androgenetic Alopecia Epidemiology Forecast Report covers data for the eight major markets (the US, France, Germany, Italy, Spain, the UK, Japan, and India).
• The report helps to identify the patient population and the unmet needs of androgenetic alopecia are highlighted along with an assessment of the disease's risk and burden.

Key Questions Answered

• What are the key findings of androgenetic alopecia epidemiology in the 8 major markets?
• What will be the total number of patients with androgenetic alopecia across the 8 major markets during the forecast period?
• What was the country-wise prevalence of androgenetic alopecia in the 8 major markets in the historical period?
• Which country will have the highest number of androgenetic alopecia patients during the forecast period of 2025-2034?
• Which key factors would influence the shift in the patient population of androgenetic alopecia during the forecast period of 2025-2034?
• What are the currently available treatments for androgenetic alopecia?
• What are the disease risks, signs, symptoms, and unmet needs of androgenetic alopecia?

This product will be delivered within 3-5 business days.